Adverse Adolescent Pathways to Substance Use
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age12-14
SponsorUniversity of North Carolina, Chapel Hill
About this trial
Purpose: This 5-year R01 study will elucidate the role of maturational change across adolescence in neural connectivity and physiological stress responses in the relationship between anxiety and adverse pathways to substance use (APSU). Participants: Children (N=200) aged 12-14 with symptoms of anxiety and their legal caregiver will be recruited from clinical and community sources. Procedures: Youth participants will complete several questionnaires and interviews, undergo neuroimaging while performing cognitive tasks, and have their heart rate and skin conductance monitored during a mildly stressful task. Caregivers will complete several questionnaires.
Eligibility criteria
Qualifiers
Male or female
12-14 years old,
Report symptoms of anxiety
Understand and sign an assent, and parents will sign a permission and a consent document in English
Disqualifiers
Has any foreign metal objects or implants as determined by the safety questionnaires (e.g., bone screws, shunts or body piercing that can't be removed, etc.)
Has been diagnosed with psychosis or a severe emotional disturbance.
Has used alcohol, tobacco, or marijuana more than 3 times.
Is pregnant. Girls who self-report pregnancy may not participate in the stress evaluation or the MRI scan.
Trial design
Treatments tested in this trial
- Trier Social Stress Test
Treatment groups
180 Participants
are divided into 1 treatment groupSponsors and collaborators
University of North Carolina, Chapel Hill
Lead sponsor
National Institute on Drug Abuse (NIDA)
Collaborator
RTI International
Collaborator
Source ClinicalTrials.gov